X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs STERLING BIOTECH - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES STERLING BIOTECH DIVIS LABORATORIES/
STERLING BIOTECH
 
P/E (TTM) x 31.3 -1.8 - View Chart
P/BV x 5.4 0.1 7,699.3% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 DIVIS LABORATORIES   STERLING BIOTECH
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
STERLING BIOTECH
Dec-13
DIVIS LABORATORIES/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,22211 11,638.1%   
Low Rs7843 23,058.8%   
Sales per share (Unadj.) Rs153.126.8 571.1%  
Earnings per share (Unadj.) Rs39.9-15.0 -267.1%  
Cash flow per share (Unadj.) Rs44.6-5.5 -816.3%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.854.9 367.7%  
Shares outstanding (eoy) m265.47267.87 99.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.60.3 2,526.9%   
Avg P/E ratio x25.1-0.5 -5,403.7%  
P/CF ratio (eoy) x22.5-1.3 -1,768.0%  
Price / Book Value ratio x5.00.1 3,924.7%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2661,862 14,302.3%   
No. of employees `0009.71.4 719.0%   
Total wages/salary Rs m4,687547 857.2%   
Avg. sales/employee Rs Th4,175.05,303.3 78.7%   
Avg. wages/employee Rs Th481.5403.8 119.2%   
Avg. net profit/employee Rs Th1,089.3-2,959.0 -36.8%   
INCOME DATA
Net Sales Rs m40,6437,181 566.0%  
Other income Rs m74943 1,758.0%   
Total revenues Rs m41,3927,223 573.0%   
Gross profit Rs m14,460947 1,527.1%  
Depreciation Rs m1,2332,543 48.5%   
Interest Rs m234,377 0.5%   
Profit before tax Rs m13,953-5,931 -235.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349-1,924 -174.0%   
Profit after tax Rs m10,604-4,007 -264.7%  
Gross profit margin %35.613.2 269.8%  
Effective tax rate %24.032.4 74.0%   
Net profit margin %26.1-55.8 -46.8%  
BALANCE SHEET DATA
Current assets Rs m40,10514,335 279.8%   
Current liabilities Rs m6,59549,809 13.2%   
Net working cap to sales %82.5-494.0 -16.7%  
Current ratio x6.10.3 2,113.2%  
Inventory Days Days119403 29.4%  
Debtors Days Days81171 47.3%  
Net fixed assets Rs m19,99555,432 36.1%   
Share capital Rs m531268 198.2%   
"Free" reserves Rs m53,04313,935 380.6%   
Net worth Rs m53,57414,701 364.4%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m61,58573,988 83.2%  
Interest coverage x618.4-0.4 -174,218.3%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.70.1 680.0%   
Return on assets %17.30.5 3,445.0%  
Return on equity %19.8-27.3 -72.6%  
Return on capital %26.1-6.4 -406.0%  
Exports to sales %025.9 0.0%   
Imports to sales %25.20.2 14,857.4%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs m10,25912 84,094.2%   
Fx inflow Rs m35,3841,860 1,902.6%   
Fx outflow Rs m10,39925 41,778.5%   
Net fx Rs m24,9851,835 1,361.7%   
CASH FLOW
From Operations Rs m11,4931,719 668.7%  
From Investments Rs m-11,372-3,148 361.2%  
From Financial Activity Rs m-931,426 -6.5%  
Net Cashflow Rs m28-3 -835.3%  

Share Holding

Indian Promoters % 52.0 33.9 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.0 -  
FIIs % 19.0 9.9 191.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.2 39.3 43.8%  
Shareholders   31,796 21,482 148.0%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - GSK PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS